Patient-centered diabetes care best in those with high HbA1c

Patient-centered diabetes care best in those with high HbA1c
Patient-centered diabetes care is most effective when targeted to patients with HbA1c >8.5 percent, according to a study published online Aug. 15 in Diabetes Care.

(HealthDay)—Patient-centered diabetes care is most effective when targeted to patients with HbA1c >8.5 percent, according to a study published online Aug. 15 in Diabetes Care.

Annabelle S. Slingerland, M.D., M.P.H., from the Leiden University Medical Center in the Netherlands, and colleagues randomized 506 patients with seen at 13 hospitals (cluster-randomized) to patient-centered (237 patients) or usual care (controls; 269 patients). Change in HbA1c, quality-adjusted life years (QALYs), and costs were the outcomes of interest. Patients were stratified by baseline HbA1c: <7.0 percent (53 mmol/mol), 7.0 to 8.5 percent, and >8.5 percent (69 mmol/mol).

The researchers found that patient-centered care was most effective and cost-effective in those with baseline HbA1c >8.5 percent, with HbA1c reduction after one year of 0.83 percent and an incremental cost-effectiveness ratio (ICER) of US$261 per QALY. This would translate to a lifetime gain of 0.54 QALYs at a cost of US$3,482 (ICER, US$6,443/QALY). For those with baseline HbA1c 7.0 to 8.5 percent, there was a gain of 0.24 QALY at a cost of US$4,731 (ICER, US$20,086/QALY). For patients with a baseline HbA1c <7.0 percent, care was not cost-effective.

"Patient-centered care is more valuable when targeted to patients with HbA1c >8.5 percent (69 mmol/mol), confirming clinical intuition," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Peer coaching model beneficial for patients with diabetes

Apr 03, 2013

(HealthDay)—Health coaching by peers is associated with a significant reduction in hemoglobin A1c (HbA1c) levels among patients treated in public health clinics, according to research published in the March/April ...

Lixisenatide non-inferior to exenatide for diabetes

Jun 07, 2013

(HealthDay)—In adults with type 2 diabetes not adequately controlled with metformin, lixisenatide once daily offers diabetes control similar to that of exenatide twice daily, with some added benefits, according ...

Recommended for you

Higher HDL cholesterol may help protect against cancer

Sep 26, 2014

(HealthDay)—Higher levels of high-density lipoprotein cholesterol (HDL-C) are associated with a decreased risk of cancer among individuals with type 2 diabetes, according to a study published online Sept. ...

Obesity isn't sole cause of type 2 diabetes

Sep 25, 2014

(HealthDay)—Although the type 2 diabetes epidemic is commonly linked to being overweight or obese, excess weight isn't the only factor driving the trend, new research suggests.

User comments